Influenza
Conditions
Keywords
Influenza, Fluzone® (Influenza Virus Vaccine) 2012-2013 Formulation, Influenza virus vaccine, Trivalent Inactivated Influenza Vaccine
Brief summary
The aim of this clinical study is to demonstrate safety and immunogenicity of Fluzone vaccine. Objective: * To describe the safety of the 2012-2013 formulation of Fluzone vaccine, administered in a 1- or 2-dose schedule, in accordance with Advisory Committee on Immunization Practices (ACIP) recommendations, in children 6 months to \< 9 years of age. Observational Objectives: * To describe the immunogenicity of the 2012-2013 formulation of Fluzone vaccine, administered in a 1- or 2-dose schedule in accordance with ACIP recommendations, in children 6 months to \< 9 years of age. * To submit remaining available sera from subjects to the Center for Biologics Evaluation and Research (CBER) for further analysis by the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) to support selection and recommendation of strains for subsequent years' influenza vaccines.
Detailed description
All participants will receive Fluzone vaccine during Visit 1. For subjects receiving 2 doses of influenza vaccine, per ACIP guidance, a second dose of Fluzone vaccine will be administered during Visit 2. Total duration of participation in the study is approximately 28 days for participants receiving 1 dose and 56 days for those receiving 2 doses of Fluzone vaccine.
Interventions
BIOLOGICALFluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose
0.25 mL dose, Intramuscular
BIOLOGICALFluzone®; Influenza Virus Vaccine, No Preservative
0.5 mL dose, Intramuscular
Sponsors
Sanofi Pasteur, a Sanofi Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 8 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject is 6 months to \< 9 years of age on the day of inclusion * Parent/guardian is willing and able to attend scheduled visits and to comply with the study procedures during the entire duration of the study * Assent form has been signed and dated by subjects 7 to \< 9 years of age, and informed consent form has been signed and dated by parent(s) or another legally acceptable representative * For subjects 6 months to \< 24 months of age, born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg (5.5 lbs).
Exclusion criteria
* Known systemic hypersensitivity to eggs, chicken proteins, latex, or any of the vaccine components, or a history of a life-threatening reaction to Fluzone vaccine or to a vaccine containing any of the same substances (the complete list of vaccine components is included in the Prescribing Information) * History of serious adverse reaction to any influenza vaccine * Receipt of any vaccine within 30 days before receiving study vaccine, or plans to receive another vaccine before Visit 2 for subjects receiving 1 influenza vaccine or Visit 3 for subjects receiving 2 doses of influenza vaccine * Participation in another interventional clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 30 days preceding the first study vaccination or during the course of the study unless no intervention for the other study occurred within the 30 days prior to the first study vaccination and none are planned before the subject would complete safety surveillance for the present study * Prior vaccination with any formulation of 2012-2013 influenza vaccine * Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, which may be a contraindication for intramuscular (IM) vaccination, at the discretion of the Investigator * Thrombocytopenia, which may be a contraindication for IM vaccination, at the discretion of the Investigator * Any condition that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine * Personal history of Guillain-Barré syndrome * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * Personal history of clinically significant developmental delay (at the discretion of the Investigator), neurologic disorder, or seizure disorder * Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion * Known seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C * Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 100.4°F). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided * Receipt of immune globulins, blood, or blood-derived products in the past 3 months * Identified as a natural or adopted child of the Investigator or an employee with direct involvement in the proposed study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Day 0 up to Day 7 post-vaccination | Solicited injection site reactions (Age 6 to \< 24 Months): Tenderness, Erythema and Swelling. Solicited systemic reactions: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite, and Irritability. Grade 3: Tenderness, Cries when injected limb is moved; Erythema and Swelling, ≥ 50 mm; Fever, \>103.1°F; Vomiting, ≥6 episodes/24 hours; Abnormal crying, \>3 hours; Drowsiness, Sleeping most of the time; Loss of appetite, Refuses ≥3 feeds/meals or most feeds/meals; Irritability, Inconsolable. Solicited injection site reactions (Age 24 Months to \< 9 Years): Pain, Erythema, and Swelling. Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating, unable to perform usual activities; Redness and Swelling, ≥ 50 mm; Fever: ≥102.1°F; Headache, Malaise, and Myalgia, Significant, prevents daily activity. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | Day 0 (pre-vaccination) and Day 28 after final vaccination | The influenza virus antibodies were measured using a hemagglutination inhibition (HAI) assay. |
| Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Day 0 (pre-vaccination) and Day 28 after final vaccination | Influenza virus antibodies were measured using a HAI assay. Seroprotection was defined as a titer ≥40 (1/dilution). |
| Number of Participants With Seroconversion Against Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Day 28 after final vaccination | Influenza virus antibodies were measured using a HAI assay. Seroconversion was defined as a pre-vaccination titer \<10 (1/dilution) and a post-vaccination titer ≥40 (1/dilution), or a pre-vaccination titer ≥10 (1/dilution) and ≥4-fold increase in titer 28 days after final vaccination. |
| Geometric Mean Titer Ratios (GMTRs) of Antibodies to Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | Day 0 (pre-vaccination) and Day 28 after final vaccination | Influenza virus antibodies were measured using a HAI assay. Geometric mean titer ratio is the geometric mean of the individual post-vaccination / pre-vaccination titer of antibodies to the influenza virus antigens |
Countries
United States
Participant flow
Recruitment details
The study participants were enrolled from 19 September 2012 to 12 December 2012 at 2 clinic centers in the United States.
Pre-assignment details
A total of 60 participants who met all of the inclusion and none of the exclusion criteria were randomized and vaccinated in this study.
Participants by arm
| Arm | Count |
|---|---|
| Age 6 to < 36 Months Group Participants 6 months to \< 36 months of age that received one or two doses of 0.25 mL of Fluzone vaccine | 30 |
| Age 3 to < 9 Years Group Participants 3 years to \< 9 years of age that received one or two doses of 0.5 mL of Fluzone vaccine | 30 |
| Total | 60 |
Baseline characteristics
| Characteristic | Age 3 to < 9 Years Group | Age 6 to < 36 Months Group | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 30 Participants | 30 Participants | 60 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 5.2 Years STANDARD_DEVIATION 1.6 | 1.8 Years STANDARD_DEVIATION 0.6 | 3.5 Years STANDARD_DEVIATION 1.2 |
| Region of Enrollment United States | 30 Participants | 30 Participants | 60 Participants |
| Sex: Female, Male Female | 13 Participants | 14 Participants | 27 Participants |
| Sex: Female, Male Male | 17 Participants | 16 Participants | 33 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 9 / 30 | 13 / 30 |
| serious Total, serious adverse events | 0 / 30 | 0 / 30 |
Outcome results
Primary
Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
Solicited injection site reactions (Age 6 to \< 24 Months): Tenderness, Erythema and Swelling. Solicited systemic reactions: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite, and Irritability. Grade 3: Tenderness, Cries when injected limb is moved; Erythema and Swelling, ≥ 50 mm; Fever, \>103.1°F; Vomiting, ≥6 episodes/24 hours; Abnormal crying, \>3 hours; Drowsiness, Sleeping most of the time; Loss of appetite, Refuses ≥3 feeds/meals or most feeds/meals; Irritability, Inconsolable. Solicited injection site reactions (Age 24 Months to \< 9 Years): Pain, Erythema, and Swelling. Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating, unable to perform usual activities; Redness and Swelling, ≥ 50 mm; Fever: ≥102.1°F; Headache, Malaise, and Myalgia, Significant, prevents daily activity.
Time frame: Day 0 up to Day 7 post-vaccination
Population: Solicited injection site reactions and systemic reactions were assessed using the Safety Analysis Set, which includes all persons who received at least one dose of study vaccine.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Injection site Swelling (N = 30, 30) | 5 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Injection site Tenderness (N =15, 0) | 1 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Injection site Pain (N =15, 30) | 8 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Injection site Pain (N = 15, 30) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Injection site Erythema (N = 30, 30) | 8 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Injection site Erythema (N = 30, 30) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Injection site Tenderness (N = 15, 0) | 8 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Injection site Swelling (N = 30, 30) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Fever (N = 30, 28) | 2 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Fever (N = 30, 28) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Headache (N = 15, 30) | 1 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Headache (N = 15, 30) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Malaise (N = 15, 30) | 4 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Malaise (N = 15, 30) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Myalgia (N = 15, 30) | 3 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Myalgia (N = 15, 30) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Vomiting (N = 15, 0) | 1 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Vomiting (N = 15, 0) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Abnormal crying (N = 15, 0) | 6 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Abnormal crying (N = 15, 0) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Drowsiness (N = 15, 0) | 5 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Drowsiness (N = 15, 0) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Loss of Appetite (N = 15, 0) | 4 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Loss of Appetite (N = 15, 0) | 0 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Irritability (N = 15, 0) | 9 Participants |
| Age 6 to < 36 Months Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Irritability (N = 15, 0) | 1 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Abnormal crying (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Injection site Tenderness (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Malaise (N = 15, 30) | 0 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Injection site Tenderness (N =15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Irritability (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Injection site Pain (N =15, 30) | 13 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Myalgia (N = 15, 30) | 2 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Injection site Pain (N = 15, 30) | 0 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Drowsiness (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Injection site Erythema (N = 30, 30) | 9 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Myalgia (N = 15, 30) | 0 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Injection site Erythema (N = 30, 30) | 0 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Loss of Appetite (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Injection site Swelling (N = 30, 30) | 7 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Vomiting (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Injection site Swelling (N = 30, 30) | 0 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Drowsiness (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Fever (N = 30, 28) | 0 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Vomiting (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Fever (N = 30, 28) | 0 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Irritability (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Headache (N = 15, 30) | 5 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Abnormal crying (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Grade 3 Headache (N = 15, 30) | 0 Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Loss of Appetite (N = 15, 0) | NA Participants |
| Age 3 to < 9 Years Group | Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Malaise (N = 15, 30) | 4 Participants |
Other Pre-specified
Geometric Mean Titer Ratios (GMTRs) of Antibodies to Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation).
Influenza virus antibodies were measured using a HAI assay. Geometric mean titer ratio is the geometric mean of the individual post-vaccination / pre-vaccination titer of antibodies to the influenza virus antigens
Time frame: Day 0 (pre-vaccination) and Day 28 after final vaccination
Population: Geometric mean titer ratios against the influenza virus antigens were assessed in the Per-protocol Analysis Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Age 6 to < 36 Months Group | Geometric Mean Titer Ratios (GMTRs) of Antibodies to Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H1N1 | 11.6 Ratio |
| Age 6 to < 36 Months Group | Geometric Mean Titer Ratios (GMTRs) of Antibodies to Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H3N2 | 16.2 Ratio |
| Age 6 to < 36 Months Group | Geometric Mean Titer Ratios (GMTRs) of Antibodies to Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | B | 1.82 Ratio |
| Age 3 to < 9 Years Group | Geometric Mean Titer Ratios (GMTRs) of Antibodies to Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H1N1 | 10.7 Ratio |
| Age 3 to < 9 Years Group | Geometric Mean Titer Ratios (GMTRs) of Antibodies to Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H3N2 | 10.3 Ratio |
| Age 3 to < 9 Years Group | Geometric Mean Titer Ratios (GMTRs) of Antibodies to Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | B | 5.34 Ratio |
Other Pre-specified
Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation).
The influenza virus antibodies were measured using a hemagglutination inhibition (HAI) assay.
Time frame: Day 0 (pre-vaccination) and Day 28 after final vaccination
Population: Geometric mean titers of antibodies against the influenza virus antigens were assessed in the Per-protocol Analysis Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Age 6 to < 36 Months Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H1N1 (post-vaccination) | 334 Titers |
| Age 6 to < 36 Months Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H3N2 (post-vaccination) | 506 Titers |
| Age 6 to < 36 Months Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H1N1 (pre-vaccination) | 20.6 Titers |
| Age 6 to < 36 Months Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | B (pre-vaccination) | 5.82 Titers |
| Age 6 to < 36 Months Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H3N2 (pre-vaccination) | 23.3 Titers |
| Age 6 to < 36 Months Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | B (post-vaccination) | 16.7 Titers |
| Age 3 to < 9 Years Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | B (post-vaccination) | 69.6 Titers |
| Age 3 to < 9 Years Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H1N1 (pre-vaccination) | 68.8 Titers |
| Age 3 to < 9 Years Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H1N1 (post-vaccination) | 864 Titers |
| Age 3 to < 9 Years Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H3N2 (pre-vaccination) | 84.8 Titers |
| Age 3 to < 9 Years Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | A/H3N2 (post-vaccination) | 895 Titers |
| Age 3 to < 9 Years Group | Geometric Mean Titers of Antibodies to Influenza Antigens Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation). | B (pre-vaccination) | 9.66 Titers |
Other Pre-specified
Number of Participants With Seroconversion Against Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
Influenza virus antibodies were measured using a HAI assay. Seroconversion was defined as a pre-vaccination titer \<10 (1/dilution) and a post-vaccination titer ≥40 (1/dilution), or a pre-vaccination titer ≥10 (1/dilution) and ≥4-fold increase in titer 28 days after final vaccination.
Time frame: Day 28 after final vaccination
Population: Seroconversion against the influenza virus antigens were assessed in the Per-protocol Analysis Set.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Age 6 to < 36 Months Group | Number of Participants With Seroconversion Against Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H1N1 | 22 Participants |
| Age 6 to < 36 Months Group | Number of Participants With Seroconversion Against Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H3N2 | 23 Participants |
| Age 6 to < 36 Months Group | Number of Participants With Seroconversion Against Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | B | 5 Participants |
| Age 3 to < 9 Years Group | Number of Participants With Seroconversion Against Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H1N1 | 22 Participants |
| Age 3 to < 9 Years Group | Number of Participants With Seroconversion Against Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H3N2 | 25 Participants |
| Age 3 to < 9 Years Group | Number of Participants With Seroconversion Against Influenza Virus Antigens Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | B | 20 Participants |
Other Pre-specified
Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
Influenza virus antibodies were measured using a HAI assay. Seroprotection was defined as a titer ≥40 (1/dilution).
Time frame: Day 0 (pre-vaccination) and Day 28 after final vaccination
Population: Seroprotection against the influenza virus antigens were assessed in the Per-protocol Analysis Set.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Age 6 to < 36 Months Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H1N1 (pre-vaccination) | 10 Participants |
| Age 6 to < 36 Months Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H1N1 (post-vaccination) | 24 Participants |
| Age 6 to < 36 Months Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H3N2 (pre-vaccination) | 11 Participants |
| Age 6 to < 36 Months Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H3N2 (post-vaccination) | 25 Participants |
| Age 6 to < 36 Months Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | B (pre-vaccination) | 1 Participants |
| Age 6 to < 36 Months Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | B (post-vaccination) | 6 Participants |
| Age 3 to < 9 Years Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | B (pre-vaccination) | 2 Participants |
| Age 3 to < 9 Years Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H1N1 (pre-vaccination) | 18 Participants |
| Age 3 to < 9 Years Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H3N2 (post-vaccination) | 30 Participants |
| Age 3 to < 9 Years Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H1N1 (post-vaccination) | 30 Participants |
| Age 3 to < 9 Years Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | B (post-vaccination) | 21 Participants |
| Age 3 to < 9 Years Group | Number of Participants With Seroprotection Before and Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | A/H3N2 (pre-vaccination) | 20 Participants |